Site-directed PEGylation of human basic fibroblast growth factor

Protein Expression and Purification

Volumn 48, Issue 1, 2006, Pages 24-27

  Wu, Xiaoping ^a   Li, Xiaokun ^a,b   Zeng, Yaoying ^a   Zheng, Qing ^a   Wu, Sixian ^a  

^a JINAN UNIVERSITY   (China)

^b WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Human basic fibroblast growth factor; Polyethylene glycol; Site directed PEGylation

Indexed keywords

CYSTEINE; FIBROBLAST GROWTH FACTOR 2; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN; SERINE;

ANIMAL; ARTICLE; CELL STRAIN 3T3; CHEMISTRY; COMPARATIVE STUDY; GENETICS; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; MOUSE; MUTATION; SITE DIRECTED MUTAGENESIS;

ANIMALS; BALB 3T3 CELLS; CYSTEINE; FIBROBLAST GROWTH FACTOR 2; HUMANS; MICE; MUTAGENESIS, SITE-DIRECTED; MUTATION; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; SERINE;

EID: 33646892823     PISSN: 10465928     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pep.2006.02.002     Document Type: Article

References (10)

1. Nishimura T., Utsunomiya Y., Hoshikawa M., Ohuchi H., and Itoh N. Structure and expression of a novel human FGF, FGF-19, expressed in the fetal brain. Biochim. Biophys. Acta 1444 1 (1999) 148-151
2. Coulier F., Pontarotti P., Roubin R., Hartung H., Goldfarb M., and Birnbaum D. Of worms and men: an evolutionary perspective on the fibroblast growth factor (FGF) and FGF receptor families. J. Mol. Evol. 44 1 (1997) 43-56
3. Gimenez-Gallego G., and Cuevas P. Fibroblast growth factors, proteins with a broad spectrum of biological activities. Neurol. Res. 16 4 (1994) 313-316
4. Liu X., and Zhu X.Z. Basic fibroblast growth factor protected forebrain against ischemia-reperfusion damage in rats. Acta Pharmacol. Sin. 19 6 (1998) 527-530
5. Lozano R.M., Pineda-Lucena A., Gonzalez C., Angeles Jimenez M., Cuevas P., Redondo-Horcajo M., Sanz J.M., Rico M., and Gimenez-Gallego G. 1H NMR structural characterization of a nonmitogenic,vasodilatory, ischemia-protector and neuromodulatory acidic fibroblast growth factor. Biochemistry 39 17 (2000) 4982-4993
6. Wu X., Su Z., Li X., Zheng Q., Huang Y., and Yuan H. High-level expression and purification of a nonmitogenic form of human acidic fibroblast growth factor in Escherichia coli. Protein Expr. Purif. 42 1 (2005) 7-11
7. Hershfield M.S. PEG-ADA replacement therapy for adenosine deaminase deficiency: an update after 8.5 years,. Clin. Immunol. Immunopathol. 76 3 Pt 2 (1995) S228-S232
8. Jen J.F., Glue P., Ezzet F., Chung C., Gupta S.K., Jacobs S., and Hajian G. Population pharmacokinetic analysis of pegylated interferon alfa-2b and interferon alfa-2b in patients with chronic hepatitis C. Clin. Pharmacol. Ther. 69 6 (2001) 407-421
9. Poynard T., McHutchison J., Manns M., Trepo C., Lindsay K., Goodman Z., Ling M.H., and Albrecht J. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 122 5 (2002) 1303-1313
10. Grace M., Youngster S., Gitlin G., Sydor W., Xie L., Westreich L., Jacobs S., Brassard D., Bausch J., and Bordens R. Structural and biologic characterization of pegylated recombinant IFN-alpha2b. J. Interferon Cytokine Res. 21 12 (2001) 1103-1115